Merrill J. Egorin

21.7k total citations
380 papers, 14.2k citations indexed

About

Merrill J. Egorin is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Merrill J. Egorin has authored 380 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Oncology, 174 papers in Molecular Biology and 71 papers in Hematology. Recurrent topics in Merrill J. Egorin's work include Cancer Treatment and Pharmacology (90 papers), Cancer therapeutics and mechanisms (65 papers) and Chronic Myeloid Leukemia Treatments (47 papers). Merrill J. Egorin is often cited by papers focused on Cancer Treatment and Pharmacology (90 papers), Cancer therapeutics and mechanisms (65 papers) and Chronic Myeloid Leukemia Treatments (47 papers). Merrill J. Egorin collaborates with scholars based in United States, Canada and Japan. Merrill J. Egorin's co-authors include Julie L. Eiseman, Robert A. Parise, Eleanor G. Zuhowski, David A. Van Echo, Joseph Aisner, Christine M. Kearns, Theodore Lagattuta, Jan H. Beumer, Ramesh K. Ramanathan and Joseph M. Covey and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Merrill J. Egorin

378 papers receiving 13.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Merrill J. Egorin United States 66 5.9k 5.5k 2.2k 1.6k 1.6k 380 14.2k
Frank M. Balis United States 64 3.6k 0.6× 3.8k 0.7× 2.4k 1.1× 1.2k 0.8× 1.2k 0.7× 313 12.4k
Ross C. Donehower United States 66 5.7k 1.0× 10.1k 1.8× 2.7k 1.2× 1.1k 0.7× 949 0.6× 223 16.0k
Jacqueline Whang‐Peng Taiwan 63 5.6k 1.0× 5.0k 0.9× 3.1k 1.4× 1.7k 1.0× 1.7k 1.0× 319 15.0k
Doriano Fabbro Switzerland 74 12.4k 2.1× 3.7k 0.7× 1.5k 0.7× 1.2k 0.7× 2.6k 1.6× 223 20.3k
Charles Dumontet France 69 9.2k 1.6× 8.6k 1.6× 2.2k 1.0× 3.0k 1.8× 2.2k 1.4× 377 20.7k
Maurizio D’Incalci Italy 69 8.4k 1.4× 6.5k 1.2× 3.2k 1.4× 1.4k 0.9× 1.0k 0.6× 531 17.4k
Joseph R. Bertino United States 75 10.2k 1.7× 8.6k 1.6× 2.4k 1.1× 2.3k 1.4× 1.9k 1.2× 471 23.2k
Charles Erlichman United States 60 5.2k 0.9× 6.0k 1.1× 2.2k 1.0× 1.8k 1.1× 707 0.4× 313 12.0k
Rosemarie Mick United States 72 3.5k 0.6× 6.2k 1.1× 2.6k 1.2× 1.5k 0.9× 1.5k 0.9× 265 14.4k
Peter C. Adamson United States 59 3.5k 0.6× 2.7k 0.5× 2.2k 1.0× 1.3k 0.8× 1.1k 0.7× 238 11.3k

Countries citing papers authored by Merrill J. Egorin

Since Specialization
Citations

This map shows the geographic impact of Merrill J. Egorin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merrill J. Egorin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merrill J. Egorin more than expected).

Fields of papers citing papers by Merrill J. Egorin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merrill J. Egorin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merrill J. Egorin. The network helps show where Merrill J. Egorin may publish in the future.

Co-authorship network of co-authors of Merrill J. Egorin

This figure shows the co-authorship network connecting the top 25 collaborators of Merrill J. Egorin. A scholar is included among the top collaborators of Merrill J. Egorin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Merrill J. Egorin. Merrill J. Egorin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jaeckle, Kurt A., Erin Twohy, Jesse G. Dixon, et al.. (2019). Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. 143(3). 573–581. 8 indexed citations
2.
Stathis, Anastasios, Sébastien J. Hotte, Eric X. Chen, et al.. (2011). Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17(6). 1582–1590. 79 indexed citations
3.
Tse, Archie, David S. Klimstra, Mithat Gönen, et al.. (2008). A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. Clinical Cancer Research. 14(20). 6704–6711. 49 indexed citations
4.
Eiseman, Julie L., Jianxia Guo, Ramesh K. Ramanathan, et al.. (2007). Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(7). 2121–2127. 10 indexed citations
5.
Ramanathan, Ramesh K., Merrill J. Egorin, Charles Erlichman, et al.. (2007). Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results.. Molecular Cancer Therapeutics. 6. 2 indexed citations
6.
Abbosh, Philip H., Jason A. Starkey, Miloš V. Novotný, et al.. (2006). Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells. Cancer Research. 66(11). 5582–5591. 82 indexed citations
7.
Florian, Jeffry, William C. Zamboni, Julie L. Eiseman, et al.. (2006). A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts. Cancer Research. 66. 730–730. 1 indexed citations
8.
Egorin, Merrill J., Chandra P. Belani, S. C. Remick, et al.. (2006). Phase I, pharmacokinetic (PK), & pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545) in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3021–3021. 1 indexed citations
9.
Koon, Henry, Glenn J. Bubley, Liron Pantanowitz, et al.. (2004). Imatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma. Journal of Clinical Oncology. 23(5). 982–989. 115 indexed citations
10.
Akerley, Wallace, James E. Herndon, Merrill J. Egorin, et al.. (2003). Weekly, high‐dose paclitaxel in advanced lung carcinoma. Cancer. 97(10). 2480–2486. 54 indexed citations
11.
Ain, Kenneth B., et al.. (2000). Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion. Thyroid. 10(7). 587–594. 224 indexed citations
12.
Hafner, Richard, David J. Wright, Nancy E. Dunlap, et al.. (1997). Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 156(3). 918–923. 34 indexed citations
13.
Glantz, Michael, H. Choy, Wallace Akerley, et al.. (1997). Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response. Seminars in Radiation Oncology. 7. 7 indexed citations
14.
Egorin, Merrill J.. (1993). Cancer pharmacology in the elderly.. PubMed. 20(1). 43–9. 58 indexed citations
15.
Heyman, Samuel N., et al.. (1993). Glycine reduces early renal parenchymal uptake of cisplatin. Kidney International. 43(6). 1226–1228. 15 indexed citations
16.
Egorin, Merrill J., et al.. (1990). Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells.. PubMed. 50(14). 4322–7. 13 indexed citations
17.
Belani, Chandra P. & Merrill J. Egorin. (1990). Carboplatin dose optimization (I: Reply). Journal of Clinical Oncology. 8(7). 1284–1285. 3 indexed citations
18.
Egorin, Merrill J., et al.. (1987). Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.. PubMed. 47(22). 6142–6. 9 indexed citations
19.
Egorin, Merrill J., David A. Van Echo, Margaret Whitacre, et al.. (1985). Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen). Journal of Bioresource Management. 26. 155. 3 indexed citations
20.
Egorin, Merrill J., et al.. (1979). Cellular accumulation and disposition of aclacinomycin A.. PubMed. 39(11). 4396–400. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026